Locations:
Search IconSearch
April 12, 2021/Neurosciences

Characteristics of CNS Vasculitis Appear to Vary According to Affected Vessel Size

Differences between large-medium vessel and small vessel variants

Imaging of vessels in CNS vasculitis

By Ken Uchino, MD, Leonard Calabrese, DO, and Rula Hajj-Ali, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Arriving at a diagnosis of central nervous system vasculitis (CNS-V) is fraught with challenges. Clinical presentation can be quite variable, and there is no classic presentation. Further complicating matters, the condition has several mimics, brain tissue is inaccessible and there is no disease-specific test. However, advances in neuroimaging and next-generation sequencing — along with the involvement of a multidisciplinary clinical team — have added formidably to our knowledge of CNS-V.

Recently, two different disease subtypes have been postulated: the small vessel variant (SVV) and large-medium vessel variant (LMVV).1 We sought to clarify the clinical characteristics, brain MRI findings and diagnostic accuracy of high-resolution vessel wall image (HR-VWI) and brain biopsy according to the affected vessel size in CNS-V patients. We discuss the results of this study in a poster presented at ACR Convergence 2020.2

Distinguishing between LMVV and SVV

Using Cleveland Clinic’s CNS vasculopathy registry, we identified 34 CNS-V patients who underwent digital subtraction angiography (DSA) or magnetic resonance angiography (MRA) at our institution from 2012-2019. For this study, patients with cerebral vasculature indicating vasculitis in proximal or middle arterial segments had LMVV, and patients with only smaller distal branch vessel involvements or normal angiography had SVV.

Based on angiographical findings, 11 (32.4%) of the patients in our cohort were LMVV and 23 (67.6%) were SVV. Patients with LMVV had more infarcts and were more likely to have concentric vessel wall enhancement (VWE) on HR-VWI, as shown in Table 1. Meningeal/parenchymal contrast enhancement of lesion was more frequently observed in the SVV group, and the majority of patients in this group were diagnosed by brain biopsy, as shown in Table 2. Brian biopsy was positive in 100% of patients with SVV compared with only 57.1% in patients with LMVV.

Advertisement

Table 1. Brain MRI, cerebral angiogram and HR-VWI findings in CNS-V patients (LMVV vs. SVV)

LMVV(n = 11)
MRI findings, n (%)
Brain infarcts
SVV(N = 23)
11 (100.0)
P Value
14 (60.9)
0.017
Parenchymal hemorrhage
SVV(N = 23)
1 (9.1)
P Value
5 (21.7)
0.638
Subarachnoid hemorrhage
SVV(N = 23)
0 (0.0)
P Value
4 (17.4)
0.280
White matter lesion
SVV(N = 23)
2 (18.2)
P Value
12 (52.2)
0.076
Tumor-like lesion
SVV(N = 23)
0 (0.0)
P Value
8 (34.8)
0.034
Contract enhancement lesion
SVV(N = 23)
5 (45.5)
P Value
20 (87.0)
0.033
Assessment of the cerebral vascular image, n (%)
Both MRA and DSA
SVV(N = 23)
11 (100.0)
P Value
13 (56.5)
0.014
Only MRA
SVV(N = 23)
0 (0.0)
P Value
8 (34.8)
0.034
Only DSA
SVV(N = 23)
0 (0.0)
P Value
2 (8.7)
1.000
Arterial stenosis, n (%)
Proximal segment
SVV(N = 23)
7 (63.6)
P Value
0 (0.0)
< 0.001
Middle segment
SVV(N = 23)
10 (90.9)
P Value
0 (0.0)
< 0.001
Smaller distal branch
SVV(N = 23)
10 (90.0)
P Value
8 (34.8)
0.003
None
SVV(N = 23)
0 (0.0)
P Value
15 (62.5)
< 0.001
HR-VWI findings, n (%)
VWE
SVV(N = 23)
10 (100.0) [n = 10]
P Value
2 (14.2) [n = 14]
< 0.001
Concentric VWE
SVV(N = 23)
9 (90.0) [n = 10]
P Value
1 (7.1) [n = 14]
< 0.001
Eccentric VWE
SVV(N = 23)
1 (10.0)[n = 10]
P Value
1 (7.1) [n = 14]
1.000

Notes: LMVV = large-medium vessel variant; SVV = small vessel variant; MRA = magnetic resonance angiography; DSA = digital subtraction angiography; HR-VWI = high-resolution vessel wall image; VWE = vessel wall enhancement

Table 2. Brain biopsy and CSF findings in CNS-V patients (LMVV vs. SVV)

LMVV(n = 11)
Biopsy proven CNS-V, n (%)
SVV( n = 23)
4 (36.4)
P Value
18 (78.3)
0.026
Biopsy positive, n (%)
SVV( n = 23)
4 (57.1) [n = 7]
P Value
18 (100.0) [n = 18]
0.015
Pathological patterns, n (%)
Granulomatous vasculitis
SVV( n = 23)
1 (14.3) [n = 7]
P Value
1 (11.1) [n = 18]
0.490
Lymphocytic vasculitis
SVV( n = 23)
3 (42.9) [n = 7]
P Value
12 (66.7) [n = 18]
0.378
Necrotizing vasculitis
SVV( n = 23)
0 (0.0) [n = 7]
P Value
5 (27.8) [n = 18]
0.274
CSF findings, n (%)
Abnormal*
SVV( n = 23)
11 (100.0) [n = 11]
P Value
16 (80.0) [n = 20]
0.269
Pleocytosis*
SVV( n = 23)
10 (90.9) [ n = 11]
P Value
12 (60.0) [n = 20]
0.106
Elevated protein*
SVV( n = 23)
8 (72.7) [n = 11]
P Value
13 (65.0) [n = 20]
1.000

Notes: CSF = cerebral spinal fluid; SNS-V = central nervous system vasculitis; LMVV = large/medium vessel variant; SVV = small vessel variant.
*Abnormal CSF is defined by either leukocyte counts > 5 cells/mm3 (pleocytosis) or protein level > 45 mg/dl (elevated protein).

Arriving at a diagnosis of CNS-V

Diagnostic approach for CNS-V depends on the affected vessel size. In LMVV patients, the diagnosis of CNS-V is mainly based on evidence of concentric VWE on HR-VWI. By contrast, brain biopsy should be considered in patients with suspected SVV CNS-V if parenchymal enhancement of lesion is detected. In patients without VWE on HR-VWI and targeting contrast enhancement lesion, careful assessments including CSF abnormalities, DSA findings and clinical pictures are needed for the diagnosis of the CNS-V.

We take a systematic approach to the work-up of any patient suspected to have CNS-V. This approach includes a general history and physical exam, with a thorough review of symptoms associated with systemic autoimmune disease. Clinicians should look for infectious and/or malignant conditions that might be associated with many of these nonspecific symptoms, especially fever, malaise, joint pains and weight loss. When CNS-V is suspected, brain biopsy is of high yield.

References

  1. Thaler C, Kaufmann-Bühler AK, Gansukh T, et al. Neuroradiologic Characteristics of Primary Angiitis of the Central Nervous System According to the Affected Vessel Size. Clin Neuroradiol. 2019;29(1):37-44.
  2. Shimoyama T, Uchino K, Calabrese L, Hajj-ali R. Clinical Characteristics, Brain MRI Findings, and Diagnostic Approach of the Central Nervous System Vasculitis by Affected Vessel Size [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).

Advertisement

Related Articles

photo of a man sleeping at a desk, with a podcast icon overlay
March 15, 2024/Neurosciences/Podcast
Diagnosis and Management of Idiopathic Hypersomnia (Podcast)

Testing options and therapies are expanding for this poorly understood sleep disorder

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

brain scan showing perimesencephalic subarachnoid hemorrhage
Study Supports Less-Strict Monitoring for Nonaneurysmal Perimesencephalic SAH Without Hydrocephalus

Digital subtraction angiography remains central to assessment of ‘benign’ PMSAH

illustrated brain with the letters "AI" on a computer circuit board
As AI Tools Emerge, Be Proactive and Engaged to Shape Their Development

Cleveland Clinic neuromuscular specialist shares insights on AI in his field and beyond

histology image of a gray matter lesion in a multiple sclerosis brain
Study Suggests Protective Role for Microglia at Borders of Gray Matter Lesions in Progressive MS

Findings challenge dogma that microglia are exclusively destructive regardless of location in brain

series of digital-looking brain icons with a podcast button overlay on top
March 1, 2024/Neurosciences/Podcast
Harnessing the Power of AI in Medicine (Podcast)

Neurology is especially well positioned for opportunities to enhance clinical care and medical training

illustration of a neuron affected by multiple sclerosis
Clinical Trials in Progressive MS: An Assessment of Advances and Remaining Challenges

New review distills insights from studies over the past decade

photo of woman looking anxious on a couch
February 22, 2024/Neurosciences/Neuromuscular
Success of POTS Treatment Reduced by Concurrent Anxiety

Guidance from an expert on distinguishing — and co-managing — the disorders

Ad